SensoLyte™ 390 ACE2 Activity Assay Kit – Industry’s First
With
its reported relation to cardiovascular disease, kidney disease, and severe
acute respiratory syndrome (SARS), Angiotensin I converting enzyme 2 (ACE2)
has become an increasingly important therapeutic target. AnaSpec is pleased
to introduce the SensoLyte™ 390 ACE2 Activity Assay Kit - the industry’s first
assay kit for the continuous monitoring of ACE2 activity.
Angiotensin I converting enzyme
2 (ACE2), the newest member of the renin angiotensin system (RAS), is a zinc
metallopeptidase that plays a central role in the control of angiotensin peptides.1,2
ACE2 has direct effects on cardiac function,3 and is expressed
predominantly in vascular endothelial cells of the heart and the kidneys.2
It has been reported that ACE2 might protect kidneys in early stages of diabetes.4
In addition to its role in the regulation of hypertension, ACE2 is a functional
receptor for the coronavirus that causes severe acute respiratory syndrome
(SARS).5
Using a Mc-Ala/Dnp fluorescence resonance energy
transfer (FRET) peptide, the SensoLyte™ 390 ACE2 Activity Assay Kit provides
a convenient assay for high throughput screening of ACE2 inhibitors and inducers
and for continuous assay of ACE2 activity. In the intact FRET peptide the
fluorescence of Mc-Ala is quenched by Dnp. Upon cleavage into two separate
fragments by ACE2, the fluorescence of Mc-Ala is recovered, and can be monitored
at excitation/emission = 330/390 nm. Performed in a convenient 96-well microplate,
the assay can detect the activity of subnanogram levels of ACE2.
Click here to request
more information.
Related Products:
SensoLyte™ 390 Renin Assay Kit
SensoLyte™ 520 Renin Assay Kit
References
1. Katovich, MJ. et al. Exp. Physiol.
90, 299 (2005).
2. Donoghue, M. et al. Circ. Res. 87, E1 (2000).
3. Boehm, M and EG. Nabel Engl J Med. 347, 1795 (2002).
4. Ye, M. et al. J Am Soc Nephrol. 17, 3067 (2006).
5. Li, W. et al. Nature 426, 450 (2003).
